These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 17099949)
1. A new approach to drug development. Mayer D N Engl J Med; 2006 Nov; 355(19):2045; author reply 2046. PubMed ID: 17099949 [No Abstract] [Full Text] [Related]
2. Role of neurologists in the pharmaceutical industry. Peroutka SJ West J Med; 1994 Sep; 161(3):328-30. PubMed ID: 7975576 [TBL] [Abstract][Full Text] [Related]
3. A new approach to drug development. Frangioni JV N Engl J Med; 2006 Nov; 355(19):2046; author reply 2046. PubMed ID: 17099947 [No Abstract] [Full Text] [Related]
4. Litigation plays protective role--and is part of the problem. Kennett JD Mo Med; 2007; 104(1):12-3. PubMed ID: 17410818 [No Abstract] [Full Text] [Related]
5. Evidence of comparative efficacy should have a formal role in European drug approvals. Sorenson C; Naci H; Cylus J; Mossialos E BMJ; 2011 Sep; 343():d4849. PubMed ID: 21896610 [No Abstract] [Full Text] [Related]
6. A new approach to drug development. Brown S N Engl J Med; 2006 Nov; 355(19):2045; author reply 2046. PubMed ID: 17099948 [No Abstract] [Full Text] [Related]
7. Former pharma pitchman: beware of new drugs. An industry insider advises considering the older options if you need a prescription. Interview by Sarah Baldauf. Nesi T US News World Rep; 2008 Nov 3-10; 145(10):64. PubMed ID: 18998444 [No Abstract] [Full Text] [Related]
8. A new approach to drug development. Guda HE N Engl J Med; 2006 Nov; 355(19):2045; author reply 2046. PubMed ID: 17093258 [No Abstract] [Full Text] [Related]
10. Academic drug detailing: an evidence-based alternative. Kondro W CMAJ; 2007 Feb; 176(4):429-31. PubMed ID: 17296946 [No Abstract] [Full Text] [Related]
11. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Garrison LP; Towse A; Bresnahan BW Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745 [TBL] [Abstract][Full Text] [Related]
12. US drug industry bans expensive freebies for MDs, Canada raises fines. Sibbald B CMAJ; 2002 Sep; 167(5):522. PubMed ID: 12240824 [No Abstract] [Full Text] [Related]
13. Time to nip "seeding trials" in the bud. Katz KA Arch Dermatol; 2008 Mar; 144(3):403-4. PubMed ID: 18347299 [No Abstract] [Full Text] [Related]
14. Medicines and people in the Third World--the role of the industry. The Association of the Danish Pharmaceutical Industry (MEFA). Dan Med Bull; 1984 Nov; 31 Suppl 1():6-8. PubMed ID: 6518831 [No Abstract] [Full Text] [Related]
15. The marketplace can't give us the drug safety data we need. Avorn J MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636 [No Abstract] [Full Text] [Related]
18. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law. Dinh TQ Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027 [No Abstract] [Full Text] [Related]